HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing...
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end...
San Antonio Center Cleared to Commence Commercial Sales of Normal Source PlasmaState of the Art Facility has Annual Collection Capacity...
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today...
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory...
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product...
Iconic Popsicle® Flavors Reimagined as Ready-to-Drink Hard Beverages Through New Licensing Agreement NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) --...
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading...
Five Diversified, Ramping DeFi Business Lines Delivered Growth Exceeding Q4 Guidance Treasury Exceeds 1.93M HYPE, 1.92M KNTQ, & 1.00M HPL...
Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models and is the core technology of TNX-1900...
Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results...
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early...
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail TherapeuticsNEW YORK and VIENNA, March 26, 2026...
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad...
VINIA's leadership position in the market validates its superior arterial dilation and blood flow performance as well as BioHarvest's Botanical...
Backed by strong diagnostics market growth and industry consolidation, the transaction positions Axonia Medical to expand across PCR, microbiology, and...
A new age of meal replacement products is here! OCALA, FL / ACCESS Newswire / March 26, 2026 / Fortifeye...